

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/722,104 Confirmation No.: 6396
Applicants : Daniel P. Becker
Filed : November 25, 2003
Title : HETEROARYLSULFONYLMETHYL HYDROXAMIC ACIDS AND
THEIR USE AS PROTEASE INHIBITORS
TC/AU : 1625
Examiner : Davis, Zinna Northington
Docket No. : PC27788
Customer No. : 25533

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

COMMUNICATION

Dear Sir:

Applicants have reviewed the Patent Term Adjustment of 330 days assigned by the U.S. Patent and Trademark Office to Application No. 10/722,104. For reasons set forth below, Applicants respectfully submit that the Patent Term Adjustment of 330 days is incorrect. Instead, Applicants submit that the proper Patent Term Adjustment is 173 days.

Applicants agree with the determination of the USPTO that there are 422 days attributable to Patent Office delays. Applicants further agree that there are 92 Applicant delay days connected with the Response to the non-final Office Action submitted on January 17, 2007. However, Applicants respectfully submit that there are 69 Applicant delay days connected with the Request for Continuing Examination filed on September 19, 2007. Applicants further respectfully submit that there were 88 Applicant delay days connected with the payment of the Issue Fee on June 3, 2008. Finally, Applicants respectfully submit that there are 24 Applicant delay days connected with the Applicants' Petition to Revive filed on June 3, 2008. However, these 24 days are overlap days and accordingly, there are 249 total Applicant delay days.

Subtracting the 249 Applicant delay days from the 422 Patent Office delay days yields a Patent Term Adjustment of 173 days.

Respectfully submitted,

JUNE 12, 2008
Date

John H. Engclmann
John H. Engclmann
Reg. No. 28,075
Pfizer Inc.
7000 Portage Road
Kalamazoo, MI 49001
Tel. (269) 833-2532
Fax (269) 833-8897